false
0001847367
0001847367
2026-01-06
2026-01-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 6, 2026
Alumis Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-42143 |
|
86-1771129 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
280 East Grand Avenue
South San Francisco, California 94080
(Address of principal executive offices)
Registrant’s telephone number, including area code: (650) 231-6625
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
| Common Stock, $0.0001 par value per share |
|
ALMS |
|
The Nasdaq Global Select Market |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On January 6, 2026, Alumis
Inc. (the “Company” or “Alumis”) issued a press release titled “Alumis’ Envudeucitinib Delivers Leading
Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program”. A copy of the press release is filed herewith
as Exhibit 99.1 and is incorporated by reference.
Additionally, on January
6, 2026, the Company posted an updated corporate presentation to the investor section of its website. A copy of
the corporate presentation is filed herewith as Exhibit 99.2 and is incorporated by reference.
The information contained in the slides is summary information that is intended to be considered in the context of the more complete information
included in the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements
that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to
update or revise the information contained in the presentation in this Current Report on Form 8-K, although it may do so from time to
time as its management believes is appropriate. Any such update may be made through the filing of other reports or documents with the
SEC.
Forward-Looking Statements
This Current Report on Form
8-K contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,”
“believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,”
“intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will”
and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements, other than
statements of historical facts, including without limitation those regarding Alumis’s plans to submit an NDA in the second
half of 2026, the potential for envudeucitinib to transform the treatment landscape for IL-23/IL-17–driven diseases as
well as those driven by Type I interferon, the potential for envudeucitinib to meaningfully elevate care for and effectively
reduce the full burden of disease for patients with moderate-to-severe plaque psoriasis, the timing of Alumis’ topline readout
in its LUMUS Phase 2b program and statements regarding Alumis’ future plans and prospects, including development of its clinical
pipeline; and any assumptions underlying any of the foregoing, are forward-looking statements. Any forward-looking statements in
this press release are based on Alumis’ current expectations, estimates and projections only as of the date of this release
and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy,
performance or events and circumstances could differ materially from those expressed or implied in Alumis’ forward-looking
statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to whether
regulatory authorities determine that envudeucitinib in moderate-to-severe plaque psoriasis is sufficiently safe and efficacious
and grant regulatory approval; whether regulatory authorities accept for filing Alumis’ planned NDA submission; Alumis’
ability to obtain regulatory approval of and ultimately commercialize Alumis’ clinical candidates, the timing and results of
preclinical and clinical trials, Alumis’ ability to fund development activities and achieve development goals, and Alumis’
ability to protect its intellectual property. Additional information on the above risks and uncertainties and additional risks, uncertainties
and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Alumis’
filings and reports with the SEC under the heading “Risk Factors”
and elsewhere in such filings and reports, including any future reports Alumis may file with the SEC from time to time. Alumis explicitly disclaims any
obligation to update any forward-looking statements except to the extent required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| |
|
|
| 99.1 |
|
Press Release, dated January 6, 2026, titled Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program. |
| |
|
|
| 99.2 |
|
Corporate Presentation dated January 2026. |
| |
|
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Alumis Inc. |
| |
|
|
| |
By: |
/s/ John Schroer |
| |
|
John Schroer |
| |
|
Chief Financial Officer |
Dated: January 6, 2026
